Back

Cardiotoxicity in haematological diseases: are the tyrosine kinase inhibitors imatinib and nilotinib safe?

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 7 - Chronic heart failure (CHF) Cardiotoxicity of drugs ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Ana Francisco

Santa Maria University Hospital (CHULN), Lisbon Academic Medical Centre and Cardiovascular Centre , Lisbon (Portugal)

29 More presentations in this session

Presentation thumbnail
Significance of non-thyroidal illness syndrome in patients with dilated cardiomyopathy
Doctor M. Koga (Osaka, JP)
Abstract
Presentation thumbnail
Relation of focal and diffuse fibrosis assessed by cardiovascular magnetic resonance imaging to clinical outcome in heart failure with preserved ejection fraction
Doctor P. Kanagala (Liverpool, GB)
Abstract Slides
Presentation thumbnail
Hematinic predictors of hemoglobin response to intravenous iron supplementation in chronic heart failure
Associate Professor S. Caravita (Bergamo, IT)
Abstract
Presentation thumbnail
The effect of anti-HER2 therapy in biventricular deformation mechanics.
Doctor K. Keramida (Athens, GR)
Abstract Slides
Presentation thumbnail
The HER2 signaling network in human heart failure, implication for brest cancer treatment
Professor P. Leszek (Warsaw, PL)
Abstract Slides

Access the full session

Session thumbnail
Poster session 7 - Chronic heart failure (CHF)

The Event

Event poster

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources